Govindan, 2017
NCT01285609 | ipilimumab + chemotherapy vs placebo + chemotherapy
in lung cancer (metastatic) | 01/11/2017 00:00:00 | immune checkpoint inhibition for lung cancer (metastatic) in all type of patients |
KEYNOTE-021 phase 2, 2016
NCT02039674 | pembrolizumab + platinum-based CT vs platinum-based CT
in lung cancer (metastatic) | 28/10/2017 00:00:00 | immune checkpoint inhibition for lung cancer (metastatic) in all type of patients immune checkpoint inhibition for lung cancer (metastatic) in first line |
KEYNOTE-059,
NCT02335411 | pembrolizumab vs nil
in gastric or gastro-oesophageal junction cancer (advanced) | 24/10/2017 00:00:00 | immune checkpoint inhibition for gastric or gastro-oesophageal junction cancer (advanced) in all type of patients |
ATTRACTION-2, 2017
NCT02267343 | nivolumab vs placebo
in gastric or gastro-oesophageal junction cancer (advanced) | 23/10/2017 00:00:00 | immune checkpoint inhibition for gastric or gastro-oesophageal junction cancer (advanced) in all type of patients |
| durvalumab phase 1/2, | durvalumab vs nil
in urothelial carcinoma (advanced) | 21/10/2017 00:00:00 | immune checkpoint inhibition for urothelial carcinoma (advanced) in all type of patients |
CABOSUN, 2017
NCT01835158 | cabozantinib vs sunitinib
in renal-cell carcinoma (advanced) | 21/10/2017 00:00:00 | multi target TKI for renal-cell carcinoma (advanced) in all type of patients |
ALUR, 2018
NCT02604342 | alectinib vs chemotherapy
in lung cancer (metastatic) | 09/09/2017 00:00:00 | ALK inhibitors for lung cancer (metastatic) in ALK positive patients |
CheckMate-214, 2017
NCT02231749 | nivolumab + ipilimumab vs sunitinib
in renal-cell carcinoma (advanced) | 16/08/2017 00:00:00 | immune checkpoint inhibition for renal-cell carcinoma (advanced) in all type of patients |
ORIGINE, 2012
NCT00069784 | insulin glargine vs control
in diabetes type 2 | 13/08/2017 00:00:00 | glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients |
SOLO2/ENGOT-Ov21,
NCT01874353 | olaparib vs placebo
in ovarian cancer | 04/08/2017 00:00:00 | poly ADP-ribose polymerase (PARP) inhibitor for ovarian cancer in all type of patient (BRCA mutated or not) poly ADP-ribose polymerase (PARP) inhibitor for ovarian cancer in patients with BRCA mutation |
FLAURA, 2017
NCT02296125 | osimertinib vs placebo
in lung cancer (metastatic) | 04/08/2017 00:00:00 | EGFR inhibitors for lung cancer (metastatic) in all type of patients EGFR inhibitors for lung cancer (metastatic) in first line |
Checkmate-141, 2016
NCT02105636 | nivolumab vs standard treatment
in Head and neck cancer | 31/07/2017 00:00:00 | immune checkpoint inhibition for Head and neck cancer in all type of patients |
KEYNOTE-185, 2018
NCT02579863 | pembrolizumab, lenalidomide, dexametahsone vs lenalidomide, dexamethasone
in multiple myeloma | 31/07/2017 00:00:00 | immune checkpoint inhibition for multiple myeloma in all type of patients |
KEYNOTE-183, 2018
NCT02576977 | pembrolizumab + pomadoline + dexamethasone vs pomadoline + dexamethasone
in multiple myeloma | 31/07/2017 00:00:00 | immune checkpoint inhibition for multiple myeloma in all type of patients |
KEYNOTE-040,
NCT02252042 | pembrolizumab vs standard treatment
in Head and neck cancer | 30/07/2017 00:00:00 | immune checkpoint inhibition for Head and neck cancer in all type of patients |
CANTOS, 2017
NCT01327846 | canakinumab vs placebo
in post myocardial infarction | 01/07/2017 00:00:00 | anti inflammatory drugs for post acute coronary syndromes in all type of patients anti inflammatory drugs for post myocardial infarction in all type of patients |
REVEAL HPS-3 TIMI-55, 2017
NCT01252953 | anacetrapib vs placebo
in cardiovascular prevention | 01/07/2017 00:00:00 | CEPT inhibition for cardiovascular prevention in all type of patients HDL increasing drugs for cardiovascular prevention in all type of patients |
CANTOS, 2017
NCT01327846 | canakinumab vs placebo
in post acute coronary syndromes | 01/07/2017 00:00:00 | anti inflammatory drugs for post acute coronary syndromes in all type of patients anti inflammatory drugs for post myocardial infarction in all type of patients |
ARCHER 1050,
NCT01774721 | dacomitinib vs gefitinib
in lung cancer (metastatic) | 05/06/2017 00:00:00 | EGFR inhibitors for lung cancer (metastatic) in all type of patients |
| De Jong, | enzastaurin + fulvestrant vs Fulvestrant
in advanced breast cancer (metastatic) | 19/05/2017 00:00:00 | angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients |
| LEA, | bevacizumab + endocrine therapy vs endocrine therapy
in advanced breast cancer (metastatic) | 19/05/2017 00:00:00 | angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients angiogenesis inhibitors for advanced breast cancer (metastatic) in first line therapy |
| Dickler (CALGB 40503°, 2015 | Letrozole plus bevacizumab vs letrozole
in advanced breast cancer (metastatic) | 19/05/2017 00:00:00 | angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients |
Hyams,
NCT00454805 | cediranib + fulvestrant vs fulvestrant
in advanced breast cancer (metastatic) | 19/05/2017 00:00:00 | angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients |
IMvigor210,
NCT02951767 | atezolizumab vs nil
in urothelial carcinoma (advanced) | 13/05/2017 00:00:00 | immune checkpoint inhibition for urothelial carcinoma (advanced) in all type of patients |
Hokusai-VTE Cancer, 2017
NCT02073682 | edoxaban vs dalteparin
in venous thrombosis | 06/03/2017 00:00:00 | antithrombotics for venous thrombosis in patients with cancer direct oral anticoagulant (DAO) for venous thrombosis in patients with cancer |
Aphinity,
NCT01358877 | pertuzumab vs placebo
in early breast cancer | 05/03/2017 00:00:00 | HER2 inhibitors for early breast cancer in HER2 positive patients |
KEYNOTE-045, 2017
NCT02256436 | pembrolizumab vs chemotherapy
in urothelial carcinoma (advanced) | 18/02/2017 00:00:00 | immune checkpoint inhibition for urothelial carcinoma (advanced) in all type of patients |
IMVIGOR-130 (monotherapy), 0
NCT02807636 | atezolizumab vs control
in urothelial carcinoma (advanced) | 18/02/2017 00:00:00 | immune checkpoint inhibition for urothelial carcinoma (advanced) in all type of patients |
EUCLID, 2016
NCT01732822 | ticagrelor vs clopidogrel
in cardiovascular prevention | 14/11/2016 00:00:00 | antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication antiplatelets drug for peripheral vascular diseases in all type of patient |
EUCLID, 2016
NCT01732822 | ticagrelor vs clopidogrel
in peripheral vascular diseases | 14/11/2016 00:00:00 | antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication antiplatelets drug for peripheral vascular diseases in all type of patient |
